Salt Substitutes Significantly Lower High Blood Pressure Risk, Study Finds

Translate to Spanish or other 102 languages!

Using salt substitutes to reduce regular salt intake may help lower high blood pressure, research suggests. Image for illustration purposes
Using salt substitutes to reduce regular salt intake may help lower high blood pressure, research suggests. Image for illustration purposes
- Advertisement -
  • Excess salt consumption is a known risk factor for developing high blood pressure.
  • New research shows swapping regular table salt for a salt substitute could helpregulate blood pressure in older adults.
  • Salt substitutes help minimize sodium intake while increasing potassium intake, both of which are associated with healthy blood pressure levels.

Overconsumption of salt is a global driver of cardiovascular disease and high blood pressure.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/salt-substitutes-significantly-lower-high-blood-pressure-risk?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-02-13&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.
- Advertisement -